Therapeutics/Diagnostics News

Healio will present its sixth annual Disruptive Innovators Awards for gastroenterology and hepatology this fall.

Cumulative exposure to immunomodulators increased the risk for high-grade cervical intraepithelial neoplasia and cervical cancer in women with inflammatory bowel disease, according to data from Alimentary Pharmacology & Therapeutics.

The use of amoxicillin-clavulanate with prednisolone did not improve 2-month survival compared with prednisolone alone in patients hospitalized with severe alcohol-related hepatitis, according to data in JAMA.

CHICAGO — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses data showing consistent safety and efficacy of Rebyota when administered via colonoscopy for prevention of recurrent Clostridioides difficile infection.

CHICAGO — The odds of having gastric and pancreatic cancers were higher among postmenopausal women on hormone replacement therapy and remained significant after controlling for risk factors, according to data at Digestive Disease Week.

Elective sigmoid resection reduced recurrence and improved quality of life in patients with recurrent, complicated or persistent painful diverticulitis within 2 years compared with conservative treatment, according to data in JAMA Surgery.

CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease.

Compared with reoffering colonoscopy and fecal immunochemical test alone, offering a blood test as a secondary option resulted in a nearly twofold increase in colorectal cancer screening in veterans who had declined first-line screening.

A U.S. District Court judge in Delaware has denied Norwich Pharmaceuticals’ motion to modify the court’s final judgment, which blocks the FDA from approving their 550 mg rifaximin generic until Oct. 2, 2029.

An FDA advisory committee voted against approval for obeticholic acid in pre-cirrhotic patients with liver fibrosis due to nonalcoholic steatohepatitis, citing “concerning” benefit-risk profile.